BAM
KYNB

Blueshift Asset Management’s Kyntra Bio KYNB Stock Holding History

Blueshift Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-552
Closed -$166K – 784
2022
Q1 		$166K Buy
+552
New +$192K 0.02% 752
2021
Q4 		– Sell
-1,151
Closed -$294K – 976
2021
Q3 		$294K Buy
+1,151
New +$408K 0.02% 826
2020
Q4 		– Sell
-241
Closed -$247K – 751
2020
Q3 		$247K Buy
+241
New +$259K 0.03% 497
2020
Q1 		– Sell
-192
Closed -$206K – 362
2019
Q4 		$206K Buy
+192
New +$196K 0.02% 715

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Blueshift Asset Management's KYNB Position: Q2 2022 in Review

Blueshift Asset Management sold out of Kyntra Bio (KYNB) in Q2 2022, closing a stake of 552 shares — an estimated $166K sold.

Blueshift Asset Management first reported a position in KYNB in Q4 2019 and held it in 4 quarters. The position peaked at $294K in Q3 2021. 150 funds tracked by Wall St. Rank hold KYNB as of Q2 2022.

  • Blueshift Asset Management reported no remaining Kyntra Bio position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 552 Kyntra Bio shares in Q2 2022, an estimated $166K.
  • Blueshift Asset Management first reported a position in Kyntra Bio in Q4 2019 and held it in 4 quarters.
  • Blueshift Asset Management's Kyntra Bio position peaked at $294K in Q3 2021.
  • 150 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.